Literature DB >> 316989

Comparison of activity and beta-lactamase stability of cefotaxime with those of six other cephalosporins.

R P Mouton, G P Bongaerts, M van Gestel.   

Abstract

A study of the susceptibility to cefotaxime and six other cephalosporins in 213 nonselected strains of nine different bacterial species clearly showed that cefotaxime was the most active against aerobic gram-negative bacilli. The same pattern emerged with 84 cephalothin-resistant strains of five enterobacterial species, but the mean minimal inhibitory concentration values for all cephalosporins were about twofold higher in this group of strains. Cephalothin was the most active antibiotic against Staphylococcus aureus. The inoculus effect of 10 cephalothin-resistant strains was relatively small, but it was most marked for cefamandole, as compared with that of three other new cephalosporins, including cefotaxime. The susceptibility of these cephalosporins to beta-lactamases from 12 beta-lactamase-producing enterobacterial strains was determined. Half of these were slightly active against cefotaxime and had similar activity against cefuroxime. Cefoxitin was not degraded at all, and cefamandole was the most susceptible. No correlation between beta-lactamase susceptibility and minimal inhibitory concentration values of different cephalosporins was found. Cefotaxime combined high intrinsic antibiotic activity with marked resistance to beta-lactamase inactivation.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 316989      PMCID: PMC352948          DOI: 10.1128/AAC.16.6.757

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Activity of HR 756 against Haemophilus influenzae, Bacteroides fragilis and Gram-negative rods.

Authors:  F A Drasar; W Farrell; A J Howard; C Hince; T Leung; J D Williams
Journal:  J Antimicrob Chemother       Date:  1978-09       Impact factor: 5.790

2.  Cefotoxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitro.

Authors:  J M Hamilton-Miller; W Brumfitt; A V Reynolds
Journal:  J Antimicrob Chemother       Date:  1978-09       Impact factor: 5.790

3.  Lack of correlation between beta-lactamase production and susceptibility to cefamandole or cefoxitin among spontaneous mutants of Enterobacteriaceae.

Authors:  J L Ott; J R Turner; D F Mahoney
Journal:  Antimicrob Agents Chemother       Date:  1979-01       Impact factor: 5.191

4.  Cefuroxime: a new cephalosporin antibiotic with enhanced stability to enterobacterial beta-lactamases.

Authors:  D Greenwood; N J Pearson; F O'Grady
Journal:  J Antimicrob Chemother       Date:  1976-12       Impact factor: 5.790

5.  Comparison of the in vitro activities of HR756 with cephalothin, cefoxitin, and cefamandole.

Authors:  J P Sosna; P R Murray; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

6.  A comparative study of the activity of cefamandole and other cephalosporins and analysis of the beta-lactamase stability and synergy of cefamandole with aminoglycosides.

Authors:  K P Fu; H C Neu
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

7.  Cefoxitin, a semisynthetic cephamycin antibiotic: susceptibility studies.

Authors:  H Wallick; D Hendlin
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

8.  HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria.

Authors:  H C Neu; N Aswapokee; P Aswapokee; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

9.  Cefoxitin, a semisynthetic cephamycin antibiotic: resistance to beta-lactamase inactivation.

Authors:  H R Onishi; D R Daoust; S B Zimmerman; D Hendlin; E O Stapley
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

10.  Antibacterial activity of cefamandole, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin, and cephalexin.

Authors:  S Eykyn; C Jenkins; A King; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1973-06       Impact factor: 5.191

View more
  11 in total

1.  Clinical experience with cefotaxime for the therapy of bacteremias due to gram-positive organisms.

Authors:  C J Schleupner
Journal:  Infection       Date:  1985       Impact factor: 3.553

2.  Clinical experience of cefotaxime in infections caused by gram-positive pathogens.

Authors:  D Bassetti; M Solbiati; G Fraizzoli
Journal:  Infection       Date:  1985       Impact factor: 3.553

3.  Comparative beta-lactamase hydrolysis of and inhibition by 7-aminothiazolyl alpha-methoxyimino cephalosporins.

Authors:  R N Jones; H W Wilson
Journal:  Infection       Date:  1982 Sep-Oct       Impact factor: 3.553

4.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

5.  Comparative activities of 13 beta-lactam antibiotics.

Authors:  H L Muytjens; J van der Ros-van de Repe
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

6.  Carbenicillin resistance of Pseudomonas aeruginosa.

Authors:  A Rodríguez-Tebar; F Rojo; D Dámaso; D Vázquez
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

7.  Clinical efficacy of cefotaxime in serious infections.

Authors:  P H Karakusis; J M Feczko; L J Goodman; D M Hanlon; A A Harris; S Levin; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

8.  In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin.

Authors:  A Vuye; J Pijck
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

Review 9.  Recognition and clinical significance of mechanisms of bacterial resistance to beta-lactams.

Authors:  R P Mouton
Journal:  Antonie Van Leeuwenhoek       Date:  1984       Impact factor: 2.271

10.  [N-formimidoyl-thienamycin: in vitro activity in bacteria with resistance to beta-lactam antibiotics or gentamicin].

Authors:  K Bartmann; R Tarbuc
Journal:  Infection       Date:  1982 Nov-Dec       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.